Patel Rajvi, Park Jennifer, Shah Ankit, Saif Muhammad Wasif
Department of Medical Oncology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra and Feinstein Institute for Medical Research, USA.
Cancer Med J. 2020;3(1):40-48. Epub 2020 Apr 3.
COVID-19 has now been declared a global pandemic with evolving incidence rates and fatalities. It is important to identify vulnerable populations who will be impacted most by this pandemic leading to higher mortality rates compared to the general healthy population. Although older patients and patients with co-morbidities fall into this vulnerable group, patients with hematologic and oncologic malignancies on active cytotoxic treatments are at even greater risk as they are both myelosuppressed and immunosuppressed. In addition to following the universal guidelines recommended by the Centers for Disease Control (CDC), it is important to also institute guidelines for cancer centers to help protect this vulnerable population. We review the current data, risks, and recommendations for COVID-19 in cancer patients.
新型冠状病毒肺炎（COVID-19）现已被宣布为全球大流行疾病，其发病率和死亡率不断变化。识别那些与一般健康人群相比，将受到此次大流行影响最大、死亡率更高的脆弱人群至关重要。虽然老年患者和患有合并症的患者属于这一脆弱群体，但正在接受积极细胞毒性治疗的血液系统和肿瘤恶性肿瘤患者面临的风险更大，因为他们既有骨髓抑制又有免疫抑制。除遵循疾病控制中心（CDC）推荐的通用指南外，为癌症中心制定指导方针以帮助保护这一脆弱人群也很重要。我们回顾了癌症患者中COVID-19的当前数据、风险和建议。
